Quest Pharmatech Stock Performance
| QPT Stock | CAD 0.04 0.00 0.00% |
Quest PharmaTech holds a performance score of 7 on a scale of zero to a hundred. The company holds a Beta of 2.68, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Quest PharmaTech will likely underperform. Use Quest PharmaTech total risk alpha, as well as the relationship between the potential upside and kurtosis , to analyze future returns on Quest PharmaTech.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Quest PharmaTech are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Quest PharmaTech showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Ex Dividend Date 2005-07-21 |
| Begin Period Cash Flow | 374.7 K |
Quest |
Quest PharmaTech Relative Risk vs. Return Landscape
If you would invest 3.00 in Quest PharmaTech on September 2, 2024 and sell it today you would earn a total of 1.00 from holding Quest PharmaTech or generate 33.33% return on investment over 90 days. Quest PharmaTech is currently producing 1.3227% returns and takes up 13.5703% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Quest, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Quest PharmaTech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Quest PharmaTech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Quest PharmaTech, and traders can use it to determine the average amount a Quest PharmaTech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0975
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | QPT | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.57 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.32 actual daily | 26 74% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Quest PharmaTech is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Quest PharmaTech by adding it to a well-diversified portfolio.
Quest PharmaTech Fundamentals Growth
Quest Stock prices reflect investors' perceptions of the future prospects and financial health of Quest PharmaTech, and Quest PharmaTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Quest Stock performance.
| Return On Equity | -0.12 | ||||
| Return On Asset | -0.0197 | ||||
| Current Valuation | 7.44 M | ||||
| Shares Outstanding | 169.13 M | ||||
| Price To Earning | (3.09) X | ||||
| Price To Book | 0.29 X | ||||
| Price To Sales | 515.97 X | ||||
| EBITDA | (802.41 K) | ||||
| Net Income | (3.02 M) | ||||
| Cash And Equivalents | 4.41 M | ||||
| Cash Per Share | 0.03 X | ||||
| Total Debt | 1000 K | ||||
| Book Value Per Share | 0.14 X | ||||
| Cash Flow From Operations | (342.42 K) | ||||
| Earnings Per Share | (0.02) X | ||||
| Total Asset | 24.48 M | ||||
| Retained Earnings | (19.08 M) | ||||
About Quest PharmaTech Performance
Evaluating Quest PharmaTech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Quest PharmaTech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Quest PharmaTech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Quest PharmaTech Inc., a biotechnology company, develops and commercializes antibody based immunotherapeutic products for cancer. The company also owns the Photodynamic therapy technology for oncology and dermatology applications and develops Mab AR 9.6 against truncated O-glycan on MUC16 for targeted cancer therapy applications. QUEST PHARMATECH operates under Biotechnology classification in Canada and is traded on TSX Venture Exchange.Things to note about Quest PharmaTech performance evaluation
Checking the ongoing alerts about Quest PharmaTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Quest PharmaTech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Quest PharmaTech is way too risky over 90 days horizon | |
| Quest PharmaTech has some characteristics of a very speculative penny stock | |
| Quest PharmaTech appears to be risky and price may revert if volatility continues | |
| Quest PharmaTech has accumulated 1000 K in total debt. Quest PharmaTech has a current ratio of 0.39, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Quest PharmaTech until it has trouble settling it off, either with new capital or with free cash flow. So, Quest PharmaTech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Quest PharmaTech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Quest to invest in growth at high rates of return. When we think about Quest PharmaTech's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (3.02 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Quest PharmaTech has accumulated about 4.41 M in cash with (342.42 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03. | |
| Roughly 17.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Quest PharmaTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Quest PharmaTech's stock is overvalued or undervalued compared to its peers.
- Examining Quest PharmaTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Quest PharmaTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Quest PharmaTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Quest PharmaTech's stock. These opinions can provide insight into Quest PharmaTech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Quest Stock Analysis
When running Quest PharmaTech's price analysis, check to measure Quest PharmaTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quest PharmaTech is operating at the current time. Most of Quest PharmaTech's value examination focuses on studying past and present price action to predict the probability of Quest PharmaTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quest PharmaTech's price. Additionally, you may evaluate how the addition of Quest PharmaTech to your portfolios can decrease your overall portfolio volatility.